Jefferies Group LLC reaffirmed a buy rating and set a $140.00 price objective on shares of Incyte in a research report on Tuesday, February 21st. TheStreet upgraded Incyte from a "c" rating to a "b-" rating in a report on Tuesday, February 14th. Analysts set a 12-month price target of $2.42 a share. As for the mean price target, it implies upside of 20.13% from the $120.49 prior closing price. (JUNO) stock confirmed the flow of 1.96% with the final price of $25.00. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold". The stock has a consensus rating of Buy and an average target price of $139.68.
Incyte Corporation (INCY) added 6.9% to reach $128.8 in the previous trading session. Its last month's stock price volatility remained 11.91% which for the week approaches 9.95%. Institutional ownership is usually beneficial to a stock price initially, but very high institutional ownership has several shortcomings. The stock's market capitalization is $27.24 billion. There are advantages to using a moving average in your trading, as well options on what type of moving average to use.
Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.01.
Incyte Corporation (INCY)'s distance from 200 day simple moving average is 18.75 percent, its distance from 50 day simple moving average is -2.77 percent, while its distance from 20 day simple moving average is 6.13 percent. The firm had revenue of $384.08 million during the quarter, compared to analyst estimates of $359.19 million. FNY Partners Fund LP raised its position in shares of Incyte by 4,825.0% in the first quarter. The business's quarterly revenue was up 45.8% on a year-over-year basis. If you are reading this report on another website, it was copied illegally and republished in violation of USA & global copyright & trademark legislation. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/05/19/credit-suisse-group-ag-reaffirms-outperform-rating-for-incyte-co-incy-updated.html. The shares were purchased at an average cost of $124.26 per share, for a total transaction of $62,130.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
In other news, Director Jean Jacques Bienaime acquired 500 shares of Incyte stock in a transaction dated Friday, April 28th. The stock was sold at an average price of $148.72, for a total transaction of $7,436,000.00. Following the completion of the transaction, the director now directly owns 302,976 shares of the company's stock, valued at approximately $45,058,590.72. The disclosure for this purchase can be found here. That shows that the stock, according to a traditional interpretation and usage of the RSI indicator, is not particularly predisposed to a reactive price movement based on this measure If we look at the stochastic measure, the raw data over the stock's last month of action shows a score of 32.36%. Insiders own 13.70% of the company's stock. Recently, the stock has been moved -61.18% from its 200-day simple moving average. Vanguard Group Inc. raised its position in Incyte by 22.7% in the first quarter. Bank of Nova Scotia now owns 116,251 shares of the biopharmaceutical company's stock valued at $15,539,000 after buying an additional 55,384 shares during the period. State Street Corp raised its position in Incyte by 110.7% in the first quarter. Seven Bridges Advisors LLC now owns 1,867 shares of the biopharmaceutical company's stock valued at $176,000 after buying an additional 398 shares in the last quarter. Emerald Acquisition Ltd. now owns 79,526 shares of the biopharmaceutical company's stock worth $7,499,000 after buying an additional 21,034 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Incyte by 1.7% in the fourth quarter. FNY Partners Fund LP raised its position in shares of Incyte by 4,825.0% in the first quarter.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics.